BioLattice Opthalmics
BioLattice Ophthalmics, Inc. is dedicated to revolutionizing tissue repair, starting with cornea. They develop engineered cornea solutions as an alternative to donor tissue, aiming to restore vision and expand patient access to tissue repair solutions. The company focuses on transforming innovative ideas into medical products through partnerships, licensing, and de-risking technology via pre-clinical validation.
Industries
Nr. of Employees
small (1-50)
Products
Engineered corneal implant (development-stage)
A full-thickness engineered corneal implant designed to serve as an alternative to donor cornea tissue and to provide corrective vision; currently in development and pre-clinical validation stages.
Engineered corneal implant (development-stage)
A full-thickness engineered corneal implant designed to serve as an alternative to donor cornea tissue and to provide corrective vision; currently in development and pre-clinical validation stages.
Services
Acquisition of dormant academic assets and development through pre-clinical validation to prepare IP for industry licensing.
Non-clinical validation activities and translational workflows to demonstrate safety and functional performance prior to commercialization or licensing.
Identification and engagement of potential industry licensees and contract organizations to enable market access for developed technologies.
Acquisition of dormant academic assets and development through pre-clinical validation to prepare IP for industry licensing.
Non-clinical validation activities and translational workflows to demonstrate safety and functional performance prior to commercialization or licensing.
Identification and engagement of potential industry licensees and contract organizations to enable market access for developed technologies.
Expertise Areas
- Tissue engineering
- Corneal implant development
- Pre-clinical validation
- Translational commercialization
Key Technologies
- Tissue engineering
- Engineered tissue scaffolds
- Corneal implant design
- Pre-clinical validation models
News & Updates
Recognition for innovative research in tissue engineering.
Coverage of BioLattice's development of artificial tissue for cornea transplants.
An article highlighting the dedication of CEO Amelia Zellander to tissue engineering.
Awarded a grant by the National Science Foundation for tissue engineering research.
Recognition for innovative research in tissue engineering.
Coverage of BioLattice's development of artificial tissue for cornea transplants.
An article highlighting the dedication of CEO Amelia Zellander to tissue engineering.
Awarded a grant by the National Science Foundation for tissue engineering research.